Skip to main content
Celltrion Pharm Inc. logo

Celltrion Pharm Inc. — Investor Relations & Filings

Ticker · 068760 ISIN · KR7068760008 KO Manufacturing
Open in API
Filings indexed 336 across all filing types
Latest filing 2023-08-14 M&A Activity
Country KR South Korea
Listing KO 068760

About Celltrion Pharm Inc.

https://www.celltrionph.com/en-us/home/…

Celltrion Pharm Inc. is a pharmaceutical company specializing in the manufacturing and supply of chemical pharmaceuticals and biosimilar products. The company's portfolio includes treatments for various conditions, with a notable focus on biosimilars for autoimmune diseases. A key product is Remsima, a biosimilar of Infliximab, indicated for treating rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis. As an integral part of the global biopharmaceutical company Celltrion, Celltrion Pharm distributes its products to both domestic and international markets, contributing to the accessibility of advanced biologic therapies.

Recent filings

Filing Released Lang Actions
조회공시요구(풍문또는보도)에대한답변(미확정)
M&A Activity Classification · 100% confidence The document is a formal response to a regulatory inquiry (조회공시요구) from the stock exchange regarding rumors or media reports about a potential merger. It explicitly states that the merger details are 'undecided' (미확정) and provides a timeline for future updates. Since this is a regulatory disclosure regarding corporate developments that does not fit into specific categories like M&A (which usually covers definitive agreements) or other financial reports, it falls under the general regulatory filing category.
2023-08-14 Korean
반기보고서 (2023.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Celltrion Pharm, Inc. covering the period from January 1, 2023, to June 30, 2023. It contains detailed financial data, business operations, management discussions, and capital structure information. As it is a comprehensive financial report for a period shorter than a full fiscal year (a half-year report) and contains substantive financial statements and analysis, it is classified as an Interim/Quarterly Report. H1 2023
2023-08-14 Korean
지급수단별ㆍ지급기간별지급금액및분쟁조정기구에관한사항
Regulatory Filings Classification · 100% confidence The document provides specific financial data regarding payment methods, payment periods, and dispute resolution mechanisms for Celltrion Pharm. This type of detailed financial disclosure, which is not a full annual report, earnings release, or management report, but rather a specific regulatory disclosure of operational financial data, falls under the category of general regulatory filings.
2023-08-11 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is titled '임원ㆍ주요주주 특정증권등 소유상황보고서' which translates to 'Report on Ownership of Specific Securities by Executives and Major Shareholders'. This is a standard regulatory filing in South Korea (DART system) used by company insiders to report changes in their shareholdings. This corresponds to the 'Director's Dealing' category, which covers personal share transactions by company directors and executives.
2023-08-04 Korean
조회공시요구(풍문또는보도)에대한답변(미확정)
M&A Activity Classification · 100% confidence The document is a formal response to a regulatory inquiry (조회공시요구) regarding market rumors about a potential merger. It is a short, regulatory-mandated disclosure filed with the exchange to clarify the status of corporate developments. Since it does not fit into specific categories like M&A activity (which would be a definitive announcement) or other specialized reports, it falls under the general regulatory filing category.
2023-07-13 Korean
조회공시요구(풍문또는보도)(셀트리온그룹, 합병 절차 본격 돌입 보도 관련)
Regulatory Filings Classification · 100% confidence The document is a formal request from a regulatory body (KRX) to a company (Celltrion Pharm) regarding rumors or media reports about a potential merger. This is a standard regulatory inquiry/announcement process in the Korean market, which does not fit into specific categories like M&A (which would be the actual merger announcement) or financial reports. Therefore, it falls under the general regulatory filing category.
2023-07-12 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.